James Hamilton

3.1k total citations
44 papers, 1.3k citations indexed

About

James Hamilton is a scholar working on Epidemiology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, James Hamilton has authored 44 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 14 papers in Molecular Biology and 14 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in James Hamilton's work include Lipid metabolism and disorders (14 papers), Liver Disease Diagnosis and Treatment (11 papers) and RNA Interference and Gene Delivery (7 papers). James Hamilton is often cited by papers focused on Lipid metabolism and disorders (14 papers), Liver Disease Diagnosis and Treatment (11 papers) and RNA Interference and Gene Delivery (7 papers). James Hamilton collaborates with scholars based in United States, Australia and New Zealand. James Hamilton's co-authors include Bruce D. Given, Thomas Schluep, Ching‐Lung Lai, Robert G. Gish, Stephen Locarnini, Man‐Fung Yuen, David L. Lewis, Carlo Ferrari, Christine I. Wooddell and Johnson Y.N. Lau and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

James Hamilton

41 papers receiving 1.2k citations

Peers

James Hamilton

EPIDE

HEPAT

CCM

Nicholas Sanderson United Kingdom

Hua‐Guo Xu China

Xiumei Chi China

Akira Saeki Japan

Carl Jorns Sweden

Jürgen Siebler Germany

Hitoshi Ichikawa Japan

Hidehiro Murakami Japan

Xiaoxi Lu China

Nicholas Sanderson United Kingdom

James Hamilton

173 ×0.3

EPIDE

232 ×0.5

HEPAT

574 ×1.3

51 ×0.2

68 ×0.3

CCM

Citations per year, relative to James Hamilton James Hamilton (= 1×) peers Nicholas Sanderson

Countries citing papers authored by James Hamilton

Since Specialization

Citations

This map shows the geographic impact of James Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Hamilton more than expected).

Fields of papers citing papers by James Hamilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Hamilton. The network helps show where James Hamilton may publish in the future.

Co-authorship network of co-authors of James Hamilton

This figure shows the co-authorship network connecting the top 25 collaborators of James Hamilton. A scholar is included among the top collaborators of James Hamilton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Hamilton. James Hamilton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raal, Frederick J., Daniel Gaudet, David Sullivan, et al.. (2025). Zodasiran (ARO-ANG3), an investigational RNAi therapeutic, demonstrates profound and durable reductions in LDL-cholesterol, apolipoprotein B, and ANGPTL3 in patients with HoFH; gateway final results. Atherosclerosis. 407. 120374–120374. 1 indexed citations

Raal, Frederick J., Daniel Gaudet, Robert S. Rosenson, et al.. (2025). Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. The Lancet Diabetes & Endocrinology. 14(2). 123–136.

Brugarolas, James, Kathryn E. Beckermann, Brian I. Rini, et al.. (2024). A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 30(11). 2402–2411. 12 indexed citations

Huetsch, John, et al.. (2024). A First-In-Human Study of ARO-RAGE, A Novel Inhaled RNA-Interference Therapy for Asthma. A1376–A1376. 2 indexed citations

Mak, Lung‐Yi, Christine I. Wooddell, Oliver Lenz, et al.. (2024). Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut. 74(3). 440–450. 17 indexed citations

Yuan, Tingting, Szymon Kłossowski, Julia Hegge, et al.. (2024). Lung-targeted RNAi Molecules Silence Human TSLP Expression in PCLS Cultures and Humanized Mice and Suppress Pulmonary Allergic Inflammation. A4340–A4340.

Raal, Frederick J., Jean Bergeron, Gerald F. Watts, et al.. (2023). ARO-ANG3, an investigational RNAI therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 379. S43–S44. 6 indexed citations

Watts, Gerald F., Christian Schwabe, Russell L. Scott, et al.. (2023). RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nature Medicine. 29(9). 2216–2223. 65 indexed citations

Strnad, Pavel, Mattias Mandorfer, Gourab Choudhury, et al.. (2022). Fazirsiran for Liver Disease Associated with Alpha ₁ -Antitrypsin Deficiency. New England Journal of Medicine. 387(6). 514–524. 65 indexed citations

10.

Mak, Lung‐Yi, Ed Gane, Christian Schwabe, et al.. (2022). A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. Journal of Hepatology. 78(4). 684–692. 52 indexed citations

11.

Gane, Ed, Man‐Fung Yuen, Thomas N. Kakuda, et al.. (2022). JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antiviral Therapy. 27(3). 201819616–201819616. 13 indexed citations

12.

Yuen, Man‐Fung, Danny Ka‐Ho Wong, Thomas Schluep, et al.. (2021). Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut. 71(4). 789–797. 37 indexed citations

13.

Clifton, Peter, David Sullivan, John E. Baker, et al.. (2020). Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia. Circulation. 142(Suppl_3). 14 indexed citations

14.

Wooddell, Christine I., Keith Blomenkamp, Ryan M. Peterson, et al.. (2020). Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease. JCI Insight. 5(12). 40 indexed citations

15.

Butler, Andrew A., James L. Graham, Kimber L. Stanhope, et al.. (2020). Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi. Journal of Lipid Research. 61(3). 376–386. 14 indexed citations

16.

Watts, Gerald F., Christian Schwabe, Russell Scott, et al.. (2020). Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia. Circulation. 142(Suppl_3). 34 indexed citations

17.

Butler, Andrew A., James L. Graham, Kimber L. Stanhope, et al.. (2019). Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference. Journal of Lipid Research. 60(4). 805–818. 21 indexed citations

18.

Wooddell, Christine I., Man‐Fung Yuen, Henry Lik‐Yuen Chan, et al.. (2017). RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Science Translational Medicine. 9(409). 342 indexed citations

19.

Sohn, Jae Ho, Rafael Durán, Yan Zhao, et al.. (2016). Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clinical Gastroenterology and Hepatology. 15(5). 746–755.e4. 27 indexed citations

20.

McDaniel, D. Olga, James Hamilton, Warren May, et al.. (2007). Molecular Analysis of Inflammatory Markers in Trauma Patients at Risk of Postinjury Complications. The Journal of Trauma: Injury, Infection, and Critical Care. 63(1). 147–158. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact